Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors.
about
Trial Watch: Adoptive cell transfer for oncological indicationsTumor infiltrating lymphocytes in ovarian cancerIndividual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells.NKG2D CARs as cell therapy for cancer.Classification of current anticancer immunotherapiesImmunotherapeutic approaches to ovarian cancer treatment.Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumorsRigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptorNKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.Adoptive immunotherapy for cancer.NKG2D signaling in cancer immunosurveillance.Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.New Approaches for Immune Directed Treatment for Ovarian Cancer.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
P2860
Q26785545-CCE6FD7D-D3BE-4A41-903F-2AFA78C63639Q27021878-AC3CC5E0-72CD-4471-830A-FE453F39D716Q27345402-48036518-A435-4AD0-A5FA-3600924C8DF4Q33595873-20EC206E-032A-4703-ACA3-945B9C18EE1DQ35149637-8BB5BB76-E377-47DC-B346-95495A3AB1DFQ35213535-E983A124-6845-456D-A170-9D8268318475Q35673240-EE50B524-A23F-4A42-AF4E-E9326B41F01BQ36557169-A9DEFC33-39A3-4C24-8593-C5B8816A32EAQ36980241-375EDC9F-EFD2-459F-8DD2-098F6B09910DQ38170496-0D5A9C3F-9802-443D-BB2A-AEE4E10683C0Q38194944-0BE459BB-2FAE-44C5-84D4-0178D2F76722Q38730881-5B5A8053-C505-47F9-844A-4EDAA611F2ECQ38760516-155B4A31-2FF3-44B1-A1E3-7FFEE93E4C77Q38830813-C2F3A1C2-FEA3-4A20-9515-5A2A5C7D663BQ41067927-B0069B44-0821-4BC1-954D-79A23A9F4B98Q42702234-031C7DD9-5A4C-4439-A866-60C2C83AFF09Q47159409-2616FBDD-A410-4145-BA4C-59CE87A4AD96Q47561397-583456A3-8A69-4502-A669-B1AD02496486
P2860
Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Collaboration of chimeric anti ...... of established ovarian tumors.
@en
type
label
Collaboration of chimeric anti ...... of established ovarian tumors.
@en
prefLabel
Collaboration of chimeric anti ...... of established ovarian tumors.
@en
P2093
P2860
P356
P1433
P1476
Collaboration of chimeric anti ...... of established ovarian tumors.
@en
P2093
Amorette Barber
Charles L Sentman
Paul Spear
P2860
P304
P356
10.4161/ONCI.23564
P577
2013-04-01T00:00:00Z